By Janelle Lawrence and Susan Decker, Bloomberg News
Momenta Pharmaceuticals Inc. lost a patent- infringement trial against Amphastar Pharmaceuticals Inc. over a process to make generic versions of the blood-thinner Lovenox.
Momenta pledged to appeal.
A Momenta patent is invalid, a federal jury in Boston decided Friday. Momenta dropped as much as 3 percent on the news, while Amphastar rose 2.6 percent.
Momenta and Novartis AG’s Sandoz unit had said they were entitled to $1 billion because of lost sales to Amphastar.
That’s almost four times the annual sales of Amphastar.
The patent is for a process used to test ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.